US FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, a First for the Rare Condition
The US FDA has approved an expanded indication for IMCIVREE (setmelanotide), developed by Rhythm Pharmaceuticals, to treat acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older. The IMCIVREE FDA approval makes it the first and only therapy authorized for this rare disease, which is characterized by accelerated and sustained weight gain following hypothalamic injury or dysfunction. The decision represents the third US indication for the melanocortin-4 receptor (MC4R) agonist, which was originally licensed from Ipsen and first approved in 2020 for obesity caused by POMC, PCSK1, or LEPR deficiency, with a subsequent label expansion to Bardet-Biedl syndrome in 2022.
The approved indication covers reduction of excess body weight and long-term maintenance of that reduction. Acquired hypothalamic obesity most frequently develops after the growth or treatment of craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumors, though it can also follow traumatic brain injury, stroke, or central nervous system inflammation. The company estimates approximately 10,000 people in the US are living with the condition. Setmelanotide is administered as a daily subcutaneous injection and acts by directly agonizing MC4R, a receptor in the hypothalamus that regulates hunger, energy expenditure, and body weight — the same pathway disrupted by hypothalamic injury.
The approval was supported by the global Phase III TRANSCEND trial, a randomized, double-blind, placebo-controlled study enrolling 142 patients with acquired hypothalamic obesity. The trial met its primary endpoint: participants receiving setmelanotide (n=94) achieved a mean BMI reduction of -15.8% from baseline at 52 weeks, compared with a +2.6% increase among those on placebo (n=48), yielding a placebo-adjusted BMI reduction of -18.4% (p<0.0001). Setmelanotide was generally well tolerated, the company said. The most common adverse events affecting more than 20% of participants were skin hyperpigmentation, nausea, vomiting, and headache. The prescribing information also carries warnings regarding depression and suicidal ideation, disturbance in sexual arousal, hypersensitivity reactions, acute adrenal insufficiency in patients with secondary adrenal insufficiency, and sodium imbalance in patients with concurrent central diabetes insipidus.
Prior to this approval, patients with acquired hypothalamic obesity had no FDA-authorized pharmacotherapy. Standard management consisted of lifestyle interventions — dietary counseling, physical activity programs, and behavioral therapy — which have demonstrated minimal sustained benefit owing to the underlying neuroendocrine disruption. Off-label use of agents including GLP-1 receptor agonists, dextroamphetamine, and octreotide produced inconsistent results, and bariatric surgery in this population has yielded outcomes inferior to those observed in common obesity, with high rates of weight regain. The condition frequently presents in children following treatment for craniopharyngioma, adding urgency to the need for pediatric-appropriate therapies. Setmelanotide is distinct from the GLP-1 receptor agonists and dual agonists that have reshaped the broader obesity treatment landscape in recent years — drugs such as semaglutide and tirzepatide — in that it targets the specific melanocortin pathway dysfunction underlying hypothalamic obesity rather than acting through incretin-mediated mechanisms. No other molecules are in late-stage clinical development for this indication, leaving IMCIVREE (setmelanotide) as the sole mechanism-directed hypothalamic obesity treatment option for these patients. Rhythm Pharmaceuticals said the drug is available to patients in the US immediately.
Spot something wrong? Report an issue with this article